The DOI matches its Crossref record; 332 of the 332 references it cites were found in a registry or an index.
A Modern Approach to Dyslipidemia
Open accessAbstract
Lipid disorders involving derangements in serum cholesterol, triglycerides, or both are commonly encountered in clinical practice and often have implications for cardiovascular risk and overall health. Recent advances in knowledge, recommendations, and treatment options have necessitated an updated approach to these disorders. Older classification schemes have outlived their usefulness, yielding to an approach based on the primary lipid disturbance identified on a routine lipid panel as a practical starting point. Although monogenic dyslipidemias exist and are important to identify, most individuals with lipid disorders have polygenic predisposition, often in the context of secondary factors such as obesity and type 2 diabetes. With regard to cardiovascular disease, elevated low-density lipoprotein cholesterol is essentially causal, and clinical practice guidelines worldwide have recommended treatment thresholds and targets for this variable. Furthermore, recent studies have established elevated triglycerides as a cardiovascular risk factor, whereas depressed high-density lipoprotein cholesterol now appears less contributory than was previously believed. An updated approach to diagnosis and risk assessment may include measurement of secondary lipid variables such as apolipoprotein B and lipoprotein(a), together with selective use of genetic testing to diagnose rare monogenic dyslipidemias such as familial hypercholesterolemia or familial chylomicronemia syndrome. The ongoing development of new agents—especially antisense RNA and monoclonal antibodies—targeting dyslipidemias will provide additional management options, which in turn motivates discussion on how best to incorporate them into current treatment algorithms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Estruch, R., Martínez-González, M. A., Corella, D., Salas-Salvadó, J., Fitó, M., Chiva-Blanch, G., Fiol, M., Gómez-Gracia, E., Arós, F., Lapetra, J., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30085-7 · Cited by 195
RetractedFriedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Lusis, A. J. (2000) · Nature · doi:10.1038/35025203 · Cited by 4,839
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationGoff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0183-z · Cited by 2,953 · cited 1×
“9 mmol/L [175 and 884 mg/dL]), where the clinical consequence is excess ASCVD risk, vs severe HTG (ie, TG >10 mmol/L [>885 mg/dL]), where there is increased risk of pancreatitis (158).”
BackgroundNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
ADOLESCENTS, E. P. O. I. G. F. C. H. A. R. R. I. C. A. (2011) · Pediatrics · doi:10.1542/peds.2009-2107c · Cited by 2,585
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Cholesterol-lowering effects of dietary fiber: a meta-analysis
Brown, L., Rosner, B., Willett, W. W., & Sacks, F. M. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.1.30 · Cited by 1,857
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Self-citationNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Bile acids: regulation of synthesis
Chiang, J. Y. L. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900010-jlr200 · Cited by 1,515
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Self-citationSarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 2×
“Analyses that have adjusted for confounding factors have largely concluded that elevated TG is an independent risk factor for ASCVD; this is especially true for nonfasting TG levels (65-68).”
BackgroundBruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
Lipid screening and cardiovascular health in childhood
Daniels, S. R., Greer, F. R., & and the Committee on Nutrition (2008) · Pediatrics · doi:10.1542/peds.2008-1349 · Cited by 1,178
Nicholls, S. J., Puri, R., Anderson, T., Ballantyne, C. M., Cho, L., Kastelein, J. J. P., Koenig, W., Somaratne, R., Kassahun, H., Yang, J., et al. (2016) · JAMA · doi:10.1001/jama.2016.16951 · Cited by 1,178
Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Grover, S., Gupta, M., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.510 · Cited by 1,173
Self-citationLipoprotein(a) Reduction in Persons with Cardiovascular Disease
Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1905239 · Cited by 1,094
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationHippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J., May, M., & Brindle, P. (2007) · BMJ · doi:10.1136/bmj.39261.471806.55 · Cited by 1,038
Nicholls, S. J., Lincoff, A. M., Garcia, M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., et al. (2020) · JAMA · doi:10.1001/jama.2020.22258 · Cited by 1,028 · cited 1×
“A comparable study that used a mixture of omega-3 fatty acids was negative with respect to ASCVD outcomes (290), suggesting that purified EPA might have unique and pleiotropic effects to reduce ASCVD risk.”
ResultTriglyceride Metabolism in the Liver
Alves‐Bezerra, M., & Cohen, D. E. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c170012 · Cited by 1,016
Boerwinkle, E., Leffert, C. C., Lin, J., Lackner, C., Chiesa, G., & Hobbs, H. H. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115855 · Cited by 962
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000624 · Cited by 907
Wiegman, A., Gidding, S. S., Watts, G. F., Chapman, M. J., Ginsberg, H. N., Cuchel, M., Ose, L., Averna, M., Boileau, C., Borén, J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv157 · Cited by 891
Self-citationEvaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
McQueen, M. J., Hawken, S., Wang, X., Ounpuu, S., Sniderman, A., Probstfield, J., Steyn, K., Sanderson, J. E., Hasani, M., Volkova, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61076-4 · Cited by 864
Goff, D. C., Lloyd‐Jones, D. M., Bennett, G. C., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D. A., O’Donnell, C. J., et al. (2014) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · Cited by 851
Nordestgaard, B. G., Langsted, A., Mora, S., Kolovou, G., Baum, H., Bruckert, E., Watts, G. F., Sypniewska, G., Wiklund, O., Borén, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw152 · Cited by 847
Pearson, G. J., Thanassoulis, G., Anderson, T. J., Barry, A. R., Couture, P., Dayan, N., Francis, G. A., Genest, J., Grégoire, J., Grover, S. A., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.03.016 · Cited by 843
Self-citationKane, J. P. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450230043027 · Cited by 829
Evinacumab for Homozygous Familial Hypercholesterolemia
Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004215 · Cited by 793
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Mendelian randomization of blood lipids for coronary heart disease
Holmes, M. V., Asselbergs, F. W., Palmer, T. M., Drenos, F., Lanktree, M. B., Nelson, C. P., Dale, C. E., Padmanabhan, S., Finan, C., Swerdlow, D. I., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/eht571 · Cited by 748
Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61731-0 · Cited by 744
Self-citationMiettinen, T. A., Puska, P., Gylling, H., Vanhanen, H., & Vartiainen, E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332002 · Cited by 739
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
Versmissen, J., Oosterveer, D. M., Yazdanpanah, M., Defesche, J. C., Basart, D. C. G., Liem, A. H., Heeringa, J., Witteman, J. C., Lansberg, P. J., Kastelein, J. J. P., et al. (2008) · BMJ · doi:10.1136/bmj.a2423 · Cited by 721
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716
(2012) · PsycEXTRA Dataset · doi:10.1037/e531652012-001 · Cited by 697
Giugliano, R. P., Pedersen, T. R., Park, J.-G., De Ferrari, G. M., Gaciong, Z. A., Ceska, R., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Schiele, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32290-0 · Cited by 682
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669
Non–High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality
Cui, Y., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., Langenberg, P., Bachorik, P. S., & Bush, T. L. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1413 · Cited by 658
20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia
Luirink, I. K., Wiegman, A., Kusters, D. M., Hof, M. H., Groothoff, J. W., de Groot, E., Kastelein, J. J. P., & Hutten, B. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816454 · Cited by 654
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Self-citationHypertriglyceridemia: its etiology, effects and treatment
Yuan, G., Al-Shali, K. Z., & Hegele, R. A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060963 · Cited by 624 · cited 4×
“Clinical features of chylomicronemia include failure to thrive in infants, eruptive xanthomas, lipemia retinalis, hepatosplenomegaly, recurrent abdominal pain, nausea and vomiting, and risk of acute pancreatitis (159, 160) (Table 6).”
BackgroundInfluentialFamilial lipoprotein disorders in patients with premature coronary artery disease.
Genest, J. J., Martin-Munley, S. S., McNamara, J. R., Ordovas, J. M., Jenner, J., Myers, R. H., Silberman, S. R., Wilson, P. W., Salem, D. N., & Schaefer, E. J. (1992) · Circulation · doi:10.1161/01.cir.85.6.2025 · Cited by 596
Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review
Sniderman, A. D., Thanassoulis, G., Glavinovic, T., Navar, A. M., Pencina, M., Catapano, A., & Ference, B. A. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3780 · Cited by 593
Talmud, P. J., Shah, S., Whittall, R., Futema, M., Howard, P., Cooper, J. A., Harrison, S. C., Li, K., Drenos, F., Karpe, F., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62127-8 · Cited by 591
US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Davidson, K. W., Epling, J. W., García, F. A. R., Gillman, M. W., Kemper, A. R., Krist, A. H., et al. (2016) · JAMA · doi:10.1001/jama.2016.15450 · Cited by 589
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
Rader, D. J., Cohen, J., & Hobbs, H. H. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18925 · Cited by 560
Discontinuation of Statins in Routine Care Settings: A Cohort Study
Zhang, H., Plutzky, J., Skentzos, S., Morrison, F., Mar, P., Shubina, M., & Turchin, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-7-201304020-00004 · Cited by 548
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
Self-citationDeterminants of atherosclerosis in the young
McGill, H. C., & McMahan, C. A. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00720-6 · Cited by 538
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.034 · Cited by 529
Goodman, D. S., Hulley, S. B., Clark, L. T., Davis, C. E., Fuster, V., LaRosa, J. C., Oberman, A., Schaefer, E. J., Steinberg, D., Brown, W. V., et al. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.148.1.36 · Cited by 529
Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.04.010 · Cited by 518
Statin therapy increases lipoprotein(a) levels
Tsimikas, S., Gordts, P. L. S. M., Nora, C., Yeang, C., & Witztum, J. L. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz310 · Cited by 512 · cited 1×
“Of currently approved lipid agents, statins can elevate Lp(a) levels, but are nonetheless considered first-line treatment in patients with high Lp(a) because of their general benefit with respect to elevated ASCVD risk (240).”
BackgroundHippisley-Cox, J., & Coupland, C. (2010) · BMJ · doi:10.1136/bmj.c2197 · Cited by 512
Rosenson, R. S., Brewer, H. B., Chapman, M. J., Fazio, S., Hussain, M. M., Kontush, A., Krauss, R. M., Otvos, J. D., Remaley, A. T., & Schaefer, E. J. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.155333 · Cited by 511
Editorial: A System for Phenotyping Hyperlipoproteinemia
FREDRICKSON, D. S., & LEES, R. S. (1965) · Circulation · doi:10.1161/01.cir.31.3.321 · Cited by 507
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497
Mora, S., Otvos, J. D., Rifai, N., Rosenson, R. S., Buring, J. E., & Ridker, P. M. (2009) · Circulation · doi:10.1161/circulationaha.108.816181 · Cited by 490
Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands
Umans-Eckenhausen, M. A., Defesche, J. C., Sijbrands, E. J., Scheerder, R. L., & Kastelein, J. J. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03587-x · Cited by 489
Cohen, J. D., Brinton, E. A., Ito, M. K., & Jacobson, T. A. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.03.003 · Cited by 486
Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials
Kashani, A., Phillips, C. O., Foody, J. M., Wang, Y., Mangalmurti, S., Ko, D. T., & Krumholz, H. M. (2006) · Circulation · doi:10.1161/circulationaha.106.624890 · Cited by 474
Plasma lipoproteins: genetic influences and clinical implications
Hegele, R. A. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2481 · Cited by 462
Self-citationJacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.07.007 · Cited by 462
Podrez, E. A., Febbraio, M., Sheibani, N., Schmitt, D., Silverstein, R. L., Hajjar, D. P., Cohen, P. A., Frazier, W. A., Hoff, H. F., & Hazen, S. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8574 · Cited by 455
Familial hypercholesterolaemia
Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Hegele, R. A., Santos, R. D., & Wierzbicki, A. S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.93 · Cited by 453
Self-citationMahley, R. W., Huang, Y., & Rall, S. C. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32417-2 · Cited by 447
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity
Chalasani, N., Aljadhey, H., Kesterson, J., Murray, M. D., & Hall, S. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.015 · Cited by 441
de Ferranti, S. D., Steinberger, J., Ameduri, R., Baker, A., Gooding, H., Kelly, A. S., Mietus-Snyder, M., Mitsnefes, M. M., Peterson, A. L., St-Pierre, J., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000618 · Cited by 441
Neil, A., Cooper, J., Betteridge, J., Capps, N., McDowell, I., Durrington, P., Seed, M., Humphries, S. E., & on behalf of the Simon Broome Familial Hyperlipidaemia Register Group (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn422 · Cited by 425
(1995) · PubMed · Cited by 423
McGill, H. C., McMahan, C. A., Zieske, A. W., Sloop, G. D., Walcott, J. V., Troxclair, D. A., Malcom, G. T., Tracy, R. E., Oalmann, M. C., Strong, J. P., et al. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.8.1998 · Cited by 421
Navarese, E. P., Kołodziejczak, M., Schulze, V., Gurbel, P. A., Tantry, U., Lin, Y., Brockmeyer, M., Kandzari, D. E., Kubica, J. M., D'Agostino, R. B., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2957 · Cited by 404
SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux
Shen, W.-J., Azhar, S., & Kraemer, F. B. (2018) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021317-121550 · Cited by 395
PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
Lagace, T. A. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000114 · Cited by 372
Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy182 · Cited by 370
Self-citationIntestinal lipid absorption and lipoprotein formation
Hussain, M. M. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000084 · Cited by 363
Chylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356
Self-citationKo, D. T., Alter, D. A., Guo, H., Koh, M., Lau, G., Austin, P. C., Booth, G. L., Hogg, W., Jackevicius, C. A., Lee, D. S., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.08.038 · Cited by 340
PCSK9 inhibitors: clinical evidence and implementation
Sabatine, M. S. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0107-8 · Cited by 338
Child–Parent Familial Hypercholesterolemia Screening in Primary Care
Wald, D. S., Bestwick, J. P., Morris, J. K., Whyte, K., Jenkins, L., & Wald, N. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602777 · Cited by 320
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Khera, A. V., Chaffin, M., Zekavat, S. M., Collins, R. L., Roselli, C., Natarajan, P., Lichtman, J. H., D’Onofrio, G., Mattera, J., Dreyer, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.035658 · Cited by 315
Evinacumab in Patients with Refractory Hypercholesterolemia
Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2031049 · Cited by 302
Marston, N. A., Giugliano, R. P., Im, K., Silverman, M. G., O’Donoghue, M. L., Wiviott, S. D., Ference, B. A., & Sabatine, M. S. (2019) · Circulation · doi:10.1161/circulationaha.119.041998 · Cited by 301
Nawaz, H., Koutroumpakis, E., Easler, J., Slivka, A., Whitcomb, D. C., Singh, V. P., Yadav, D., & Papachristou, G. I. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.261 · Cited by 296
The complex molecular genetics of familial hypercholesterolaemia
Berberich, A. J., & Hegele, R. A. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0052-6 · Cited by 290
Self-citationStatin Treatment in Children With Familial Hypercholesterolemia: The Younger, the Better
Rodenburg, J., Vissers, M. N., Wiegman, A., van Trotsenburg, A. S. P., van der Graaf, A., de Groot, E., Wijburg, F. A., Kastelein, J. J. P., & Hutten, B. A. (2007) · Circulation · doi:10.1161/circulationaha.106.671016 · Cited by 286
Gaudet, D., Karwatowska-Prokopczuk, E., Baum, S. J., Hurh, E., Kingsbury, J., Bartlett, V. J., Figueroa, A. L., Piscitelli, P., Singleton, W., Witztum, J. L., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa689 · Cited by 279
N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects
Wood, F. A., Howard, J. P., Finegold, J. A., Nowbar, A. N., Thompson, D. M., Arnold, A. D., Rajkumar, C. A., Connolly, S., Cegla, J., Stride, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031173 · Cited by 274
Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis
Pedersen, S. B., Langsted, A., & Nordestgaard, B. G. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6875 · Cited by 270
An Assessment of Statin Safety by Hepatologists
Cohen, D. E., Anania, F. A., & Chalasani, N. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.014 · Cited by 269
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease
Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260 · cited 3×
“Mendelian randomization studies have linked genetic elevations in TGs to ASCVD outcomes, supporting TG as an independent risk factor after adjusting for other lipid effects, but again given the huge underlying metabolic pleiotropy associated with elevated TGs, these cannot definitively prove causation in our opinion (…”
BackgroundLipoprotein(a) and Cardiovascular Disease
Kamstrup, P. R. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa247 · Cited by 256
Nordestgaard, B. G., Langlois, M. R., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.12.005 · Cited by 246
The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis
Harper, C. R., & Jacobson, T. A. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32825a6773 · Cited by 246
Hypertriglyceridemia and atherosclerosis
Peng, J., Luo, F., Ruan, G., Peng, R., & Li, X. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0625-0 · Cited by 245
Genetics of hypertriglyceridemia
Dron, J. S., & Hegele, R. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00455 · Cited by 244 · cited 3×
“Rare biallelic loss-of-function variants in 4 genes encoding proteins that support the function of LPL—namely APOC2, APOA5, LMF1, or GPIHBP1—account for 20% of FCS cases (181).”
BackgroundSelf-citationGouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., Hughes, S. G., Gaudet, D., Hegele, R. A., O'Dea, L. S. L., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00046-2 · Cited by 232
Self-citationOuchi, Y., Sasaki, J., Arai, H., Yokote, K., Harada, K., Katayama, Y., Urabe, T., Uchida, Y., Hayashi, M., Yokota, N., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039415 · Cited by 231
Wolska, A., Dunbar, R. L., Freeman, L. A., Ueda, M., Amar, M. J., Sviridov, D. O., & Remaley, A. T. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.025 · Cited by 231
Alexander, V. J., Xia, S., Hurh, E., Hughes, S. G., O’Dea, L., Geary, R. S., Witztum, J. L., & Tsimikas, S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz209 · Cited by 231
Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes
Gudbjartsson, D. F., Thorgeirsson, G., Sulem, P., Helgadottir, A., Gylfason, A., Saemundsdottir, J., Bjornsson, E., Norddahl, G. L., Jonasdottir, A., Jonasdottir, A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.019 · Cited by 226
Severe hypertriglyceridemia is primarily polygenic
Dron, J. S., Wang, J., Cao, H., McIntyre, A. D., Iacocca, M. A., Menard, J. R., Movsesyan, I., Malloy, M. J., Pullinger, C. R., Kane, J. P., et al. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.10.006 · Cited by 222 · cited 2×
“This pattern is seen in patients with combined hyperlipidemia (CHL; former type 2B) (31), mild-to-moderate isolated hypertriglyceridemia (HTG, former type 4) (32), and severe HTG (multifactorial chylomicronemia or former type 5) (33).”
BackgroundSelf-citationWatts, G. F., Barrett, P. H. R., Ji, J., Serone, A. P., Chan, D. C., Croft, K. D., Loehrer, F., & Johnson, A. G. (2003) · Diabetes · doi:10.2337/diabetes.52.3.803 · Cited by 219
Triglycerides and Heart Disease: Still a Hypothesis?
Goldberg, I. J., Eckel, R. H., & McPherson, R. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.226100 · Cited by 219
Zhu, Y., Pan, X., Zeng, H., He, W., Xia, L., Liu, P., Zhu, Y., Chen, Y., & Lv, N. (2017) · Pancreas · doi:10.1097/mpa.0000000000000776 · Cited by 219
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212 · cited 1×
“CHL also largely overlaps with the so-called “atherogenic dyslipidemia complex,” which is associated with obesity, insulin resistance, and type 2 diabetes (227); this association reinforces the important role of secondary factors underlying this phenotype.”
BackgroundSelf-citationTriglyceride metabolism in pregnancy
(2011) · Advances in Clinical Chemistry · doi:10.1016/b978-0-12-387042-1.00007-1 · Cited by 212
Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1253 · Cited by 211 · cited 3×
“9 mmol/L (27 and 35 mg/dL) for European men and women, respectively (37).”
BackgroundInfluentialPolygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically
Wang, J., Dron, J. S., Ban, M. R., Robinson, J. F., McIntyre, A. D., Alazzam, M., Zhao, P. J., Dilliott, A. A., Cao, H., Huff, M. W., et al. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.308027 · Cited by 210
Self-citationHegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30264-5 · Cited by 204 · cited 2×
“A detailed discussion is beyond the scope here; the interested reader is referred to a recent review (128).”
BackgroundSelf-citationThe molecular basis of familial hypercholesterolemia in The Netherlands
Fouchier, S. W., Defesche, J. C., Umans-Eckenhausen, M. A., & Kastelein, J. J. (2001) · Human Genetics · doi:10.1007/s00439-001-0628-8 · Cited by 203
Arterial retention of apolipoprotein B48- and B100-containing lipoproteins in atherogenesis
Proctor, S. D., Vine, D. F., & Mamo, J. C. L. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200210000-00001 · Cited by 201
Low-density lipoprotein particle number and risk for cardiovascular disease
Cromwell, W. C., & Otvos, J. D. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0050-5 · Cited by 198
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
Robinson, J. G., Rosenson, R. S., Farnier, M., Chaudhari, U., Sasiela, W. J., Merlet, L., Miller, K., & Kastelein, J. J. P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.037 · Cited by 197
Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells.
Ettinger, W. H., Varma, V. K., Sorci-Thomas, M., Parks, J. S., Sigmon, R. C., Smith, T. K., & Verdery, R. B. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.1.8 · Cited by 195
Lipid Abnormalities in the Nephrotic Syndrome: Causes, Consequences, and Treatment
Wheeler, D. C., & Bernard, D. B. (1994) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80994-2 · Cited by 194
Xanthomas: Clinical and pathophysiological relations
Zak, A., Zeman, M., Slaby, A., & Vecka, M. (2014) · Biomedical Papers · doi:10.5507/bp.2014.016 · Cited by 194
Kramsch, D. M., Franzblau, C., & Hollander, W. (1971) · Journal of Clinical Investigation · doi:10.1172/jci106656 · Cited by 190
An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins
Hirota, T., Fujita, Y., & Ieiri, I. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1801634 · Cited by 188
Severe hypertriglyceridemia in pregnancy
Goldberg, A. S., & Hegele, R. A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1250 · Cited by 187
Self-citationWang, N., Fulcher, J., Abeysuriya, N., Park, L., Kumar, S., Di Tanna, G. L., Wilcox, I., Keech, A., Rodgers, A., & Lal, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30388-2 · Cited by 187 · cited 1×
“Lowering cholesterol is associated with a reduction in ASCVD risk, with a 20% relative risk reduction for every 1 mmol/L reduction in LDL-C (38, 39).”
BackgroundManagement of Statin Intolerance in 2018: Still More Questions Than Answers
Toth, P. P., Patti, A. M., Giglio, R. V., Nikolic, D., Castellino, G., Rizzo, M., & Banach, M. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0259-7 · Cited by 186
Serum triglycerides and risk of cardiovascular disease
Boullart, A. C. I., Graaf, J. D., & Stalenhoef, A. F. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.002 · Cited by 182
Ten-Year Follow-up After Initiation of Statin Therapy in Children With Familial Hypercholesterolemia
Kusters, D. M., Avis, H. J., de Groot, E., Wijburg, F. A., Kastelein, J. J. P., Wiegman, A., & Hutten, B. A. (2014) · JAMA · doi:10.1001/jama.2014.8892 · Cited by 176
ABCA1 and nascent HDL biogenesis
Wang, S., & Smith, J. D. (2014) · BioFactors · doi:10.1002/biof.1187 · Cited by 174
US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Davidson, K. W., Epling, J. W., García, F. A. R., Gillman, M. W., Kemper, A. R., Krist, A. H., et al. (2016) · JAMA · doi:10.1001/jama.2016.9852 · Cited by 173
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 172
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Self-citationHigh-Density Lipoprotein Cholesterol and Mortality: Too Much of a Good Thing?
Hamer, M., O’Donovan, G., & Stamatakis, E. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310587 · Cited by 171
Sandhu, S., Al-Sarraf, A., Taraboanta, C., Frohlich, J., & Francis, G. A. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-157 · Cited by 167
Role of Bempedoic Acid in Clinical Practice
Ballantyne, C. M., Bays, H. E., Catapano, A. L., Goldberg, A. C., Ray, K. K., & Saseen, J. J. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07147-5 · Cited by 167
Clinical and biochemical features of different molecular etiologies of familial chylomicronemia
Hegele, R. A., Berberich, A. J., Ban, M. R., Wang, J., Digenio, A., Alexander, V. J., D'Erasmo, L., Arca, M., Jones, A., Bruckert, E., et al. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.03.093 · Cited by 165
Self-citationCanadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018
Brunham, L. R., Ruel, I. L., Aljenedil, S., Rivière, J., Baass, A. W., Tu, J. V., Mancini, G. B. J., Raggi, P., Gupta, M., Couture, P., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.09.005 · Cited by 165
Self-citationGPIHBP1 and Lipoprotein Lipase, Partners in Plasma Triglyceride Metabolism
Young, S. G., Fong, L. G., Beigneux, A. P., Allan, C. M., He, C. H., Jiang, H., Nakajima, K., Muthuraman, M., Birrane, G., & Ploug, M. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.05.023 · Cited by 165
Dyslipidemia in Type 1 Diabetes: A Masked Danger
Vergès, B. L. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.01.015 · Cited by 163
Palabrica, T. M., Liu, A. C., Aronovitz, M. J., Furie, B., Lawn, R. M., & Furie, B. C. (1995) · Nature Medicine · doi:10.1038/nm0395-256 · Cited by 162
Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis
Chen, J.-H., Yeh, J.-H., Lai, H.-W., & Liao, C.-S. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i15.2272 · Cited by 160
Lipid transfer proteins in the assembly of apoB-containing lipoproteins
Sirwi, A., & Hussain, M. M. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r083451 · Cited by 160
Berberich, A. J., & Hegele, R. A. (2013) · Nutrients · doi:10.3390/nu5030981 · Cited by 159
Self-citationUniversal Screening for Familial Hypercholesterolemia in Children
Klančar, G., Grošelj, U., Kovač, J., Bratanič, N., Bratina, N., Podkrajšek, K. T., & Battelino, T. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.017 · Cited by 158
Hypertriglyceridemia in the genomic era: a new paradigm
Lewis, G. F., Xiao, C., & Hegele, R. A. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1062 · Cited by 152
Self-citationGenetic testing in dyslipidemia: A scientific statement from the National Lipid Association
Brown, E. E., Sturm, A. C., Cuchel, M., Braun, L. T., Duell, P. B., Underberg, J. A., Jacobson, T. A., & Hegele, R. A. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.04.011 · Cited by 148 · cited 3×
“2) is a noninvasive and cost-effective way to identify individuals with a monogenic dyslipidemia (134).”
BackgroundInfluentialSelf-citationThe pathogenesis and clinical significance of xanthelasma palpebrarum
Bergman, R. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(94)70023-0 · Cited by 145
Dangas, G., Mehran, R., Harpel, P. C., Sharma, S. K., Marcovina, S. M., Dube, G. K., Ambrose, J. A., & Fallon, J. T. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00469-0 · Cited by 144
Blom, D. J., Averna, M. R., Meagher, E. A., Theron, H. D. T., Sirtori, C. R., Hegele, R. A., Shah, P. K., Gaudet, D., Stefanutti, C., Vigna, G. B., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.028208 · Cited by 144
Self-citationFamilial chylomicronemia syndrome: an under‐recognized cause of severe hypertriglyceridaemia
Baass, A., Paquette, M., Bernard, S., & Hegele, R. A. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13016 · Cited by 144
Self-citationTrajkovska, K. T., & Topuzovska, S. (2017) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2017.7608 · Cited by 141
Effects of exercise on HDL functionality
Ruiz‐Ramie, J. J., Barber, J. L., & Sarzynski, M. A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000568 · Cited by 140
Haim, M., Benderly, M., Brunner, D., Behar, S., Graff, E., Reicher-Reiss, H., & Goldbourt, U. (1999) · Circulation · doi:10.1161/01.cir.100.5.475 · Cited by 139
Nicholls, S., Lincoff, A. M., Bays, H. E., Cho, L., Grobbee, D. E., Kastelein, J. J., Libby, P., Moriarty, P. M., Plutzky, J., Ray, K. K., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2020.10.060 · Cited by 136
Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages.
Zioncheck, T. F., Powell, L. M., Rice, G. C., et al. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115079 · Cited by 133
N-of-1 (Single-Patient) Trials for Statin-Related Myalgia
Joy, T. R., Monjed, A., Zou, G. Y., Hegele, R. A., McDonald, C. G., & Mahon, J. L. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1921 · Cited by 130
Self-citationIntestinal CD36 and Other Key Proteins of Lipid Utilization: Role in Absorption and Gut Homeostasis
Cifarelli, V., & Abumrad, N. A. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170026 · Cited by 127
Laws, A., Stefanick, M. L., & Reaven, G. M. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-2-343 · Cited by 126
Groner, J. A., Joshi, M. S., & Bauer, J. A. (2006) · PEDIATRICS · doi:10.1542/peds.2005-2992 · Cited by 122
Lysosomal acid lipase and lipid metabolism: new mechanisms, new questions, and new therapies
Zhang, H. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000507 · Cited by 120
Inclisiran for the Treatment of Cardiovascular Disease: the Orion Clinical Development Program
Stoekenbroek, R. M., Kallend, D. G., Wijngaard, P. L. J., & Kastelein, J. J. P. (2018) · Future Cardiology · doi:10.2217/fca-2018-0067 · Cited by 115
Regulation of lipoprotein lipase-mediated lipolysis of triglycerides
Basu, D., & Goldberg, I. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000676 · Cited by 114
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.01.002 · Cited by 112
Diagnosis and Management of Type I and Type V Hyperlipoproteinemia
Gotoda, T., Shirai, K., Ohta, T., Kobayashi, J., Yokoyama, S., Oikawa, S., Bujo, H., Ishibashi, S., Arai, H., Yamashita, S., et al. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.10702 · Cited by 110
Apolipoprotein E in Hyperlipidemia
Walden, C. C., & Hegele, R. A. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-12-199406150-00009 · Cited by 110
Self-citationScreening for Statin-Related Toxicity
Smith, C. C., Bernstein, L. I., Davis, R. B., Rind, D. M., & Shmerling, R. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.6.688 · Cited by 110
Hegele, R. A., Ban, M. R., Hsueh, N., Kennedy, B. A., Cao, H., Zou, G., Anand, S. S., Yusuf, S., Huff, M. W., & Wang, J. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp361 · Cited by 110
Self-citationReeskamp, L. F., Millar, J. S., Wu, L., Jansen, H., van Harskamp, D., Schierbeek, H., Gipe, D. A., Rader, D. J., Dallinga-Thie, G. M., Hovingh, G. K., et al. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315204 · Cited by 109
Heparin and Insulin in the Treatment of Hypertriglyceridemia-Induced Severe Acute Pancreatitis
Alagözlü, H., Cindoruk, M., Karakan, T., & Ünal, S. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-9006-z · Cited by 106
Familial dysbetalipoproteinemia: An underdiagnosed lipid disorder
Koopal, C., Marais, A. D., & Visseren, F. L. J. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000316 · Cited by 101 · cited 2×
“Most individuals with dysbetalipoproteinemia are homozygous for the binding-impaired apo E2 isoform encoded by the APOE E2 allele (190).”
BackgroundNew insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk
Kersten, S. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000600 · Cited by 99
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia
Khan, S. A., Naz, A., Qamar Masood, M., & Shah, R. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.08.018 · Cited by 98
Research works printed but not linked: 9
- Feingold, 2000, Introduction to lipids and lipoproteins
- Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study, Lancet., 380, 572, 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
- Berg, 2002, U.S. Preventive Services Task Force: screening for lipid disorders in adults: recommendations and rationale, Am J Nurs., 102, 91
- Tsai, 2005, Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraprotein, Clin Chim Acta., 358, 192, 10.1016/j.cccn.2005.02.008 · doi:10.1016/j.cccn.2005.02.008
- Koch, 2020, New Sampson low-density lipoprotein equation: better than Friedewald and Martin-Hopkins, Clin Chem., 66, 1120, 10.1093/clinchem/hvaa126 · doi:10.1093/clinchem/hvaa126
- Vinger, 1970, Ocular manifestations of hyperlipoproteinemia, Am J Ophthalmol., 70, 563, 10.1016/0002-9394(70)90890-1 · doi:10.1016/0002-9394(70)90890-1
- Hall, 2012, The best diagnosis is: eruptive xanthoma, Cutis., 90, 12
- US Food and Drug Administration., 2021, Statins: drug safety communication—FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy
- Kuehn, 2021, Evinacumab approval adds a new option for homozygous familial hypercholesterolemia with a hefty price tag, Circulation., 143, 2494, 10.1161/CIRCULATIONAHA.121.055463 · doi:10.1161/circulationaha.121.055463
Cited by
Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association
Javed, F., Hegele, R. A., Garg, A., Patni, N., Gaudet, D., Williams, L., Khan, M., Li, Q., & Ahmad, Z. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2025.03.013 · Cited by 60
Self-citationAdvances in treatment of Dyslipidemia
Dybiec, J., Baran, W., Dąbek, B., Fularski, P., Młynarska, E., Radzioch, E., Rysz, J., & Franczyk, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713288 · Cited by 55
Kamrul-Hasan, A. B. M., Dutta, D., Nagendra, L., Mondal, S., Bhattacharya, S., & Kalra, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.08.013 · Cited by 17
Huang, Y., Wang, Y., Xiao, Z., Yao, S., Tang, Y., Zhou, L., Wang, Q., Xie, Y., Zhang, L., Zhou, Y., et al. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03580-6 · Cited by 16
Sydhom, P., Al-Quraishi, B., Gohar, A., El-Shawaf, M., Shehata, N., Ataya, M., Sydhom, M., Awwad, N., Motawade, H., Naji, N., et al. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07798-8 · Cited by 5
“In contrast, secondary dyslip-idemias often occur in the context of metabolic syndrome and are commonly associated with obesity, alcohol intake, sedentary lifestyle, and type 2 diabetes [1, 2].”
Metadata
- Authors
- Berberich, A. J., & Hegele, R. A.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2021-10-22
- Volume
- 43
- Issue
- 4
- Pages
- 611-653
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W3205422331
- Cited by
- 469
- References
- 332
- FWCI
- 53.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Canadian Institutes of Health Research
- Heart and Stroke Foundation of Ontario (G-21-0031455)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.